← Leaderboards
Fernando J Martinez
Weill Medical Coll Of Cornell Univ
$34,787,404
Attributed
$70,479,204
Total exposure
20
Grants
17
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $8.5M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$70,479,204 · 20
By mechanism
R01$29,971,889 · 5
UH3$11,596,602 · 1
RC2$7,915,507 · 1
R33$5,723,087 · 1
U10$3,486,570 · 2
T32$2,706,211 · 1
Top collaborators
- Meilan K Han16 shared
- Imre Noth7 shared
- Augustine M Choi6 shared
- Kevin J Anstrom5 shared
- Harold A Chapman5 shared
- Jeffrey L Curtis5 shared
- Catherine A Spino5 shared
- Gary B. Huffnagle4 shared
Most similar at Weill Medical Coll Of Cornell Univ
Same institution · by research overlap
- Vivek Mittal$10,850,597
- Linda Theresa Vahdat$1,571,187
- Augustine M Choi$36,719,348
Others in their field
Top investigators on “Lung”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$372,040,227
- Chanza Baytop · Westat, Inc.$271,217,917
- Richard K. Wilson · Washington University$201,818,043
- Walter John Curran · Thomas Jefferson University$112,093,071
Research focus
LungResponseLinkPhysiologicalBaseExhibitsInnovationSiteCohortPathway InteractionsNational Heart, Lung, And Blood InstituteClinical TrialsDiagnosticDisease ProgressionIdiopathic Pulmonary FibrosisSpirometryPulmonary FibrosisFundingDiagnosisAcuteChronic Obstructive Airway DiseaseInflammationLung DiseasesEnrollment
Grant awards (83)
Phase 1 study of oral epigallocatechin-3-gallate (EGCG) in IPF patients$1,763,207
R33 · FY2025 · HL · contact PI
1/2 Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases study$1,085,815
UH3 · FY2025 · HL · contact PI
Clinical Biorepository Core$340,062
P01 · FY2025 · HL · contact PI
Understanding the Origins of Early COPD$2,168,770
R01 · FY2024 · HL · contact PI
Phase 1 study of oral epigallocatechin-3-gallate (EGCG) in IPF patients$1,758,766
R33 · FY2024 · HL · contact PI
1/2 Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases study$1,110,651
UH3 · FY2024 · HL · contact PI
Clinical Biorepository Core$533,698
P01 · FY2024 · HL · contact PI
1/2 Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases study$132,310
UH3 · FY2024 · HL · contact PI
Phase 1 study of oral epigallocatechin-3-gallate (EGCG) in IPF patients$48,139
R33 · FY2024 · HL · contact PI
1/2 Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases study$3,032,451
UH3 · FY2023 · HL · contact PI
Phase 1 study of oral epigallocatechin-3-gallate (EGCG) in IPF patients$2,152,975
R33 · FY2023 · HL · contact PI
Understanding the Origins of Early COPD$2,101,189
R01 · FY2023 · HL · contact PI
Multidisciplinary Approach Training in Respiratory Research$663,264
T32 · FY2023 · HL · contact PI
Clinical Biorepository Core$521,412
P01 · FY2023 · HL · contact PI
1/2 Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases study$3,487,084
UH3 · FY2022 · HL · contact PI
Understanding the Origins of Early COPD$2,241,348
R01 · FY2022 · HL · contact PI
Clinical Biorepository Core$521,221
P01 · FY2022 · HL · contact PI
Multidisciplinary Approach Training in Respiratory Research$494,154
T32 · FY2022 · HL · contact PI
Phase 1 study of oral epigallocatechin-3-gallate (EGCG) in IPF patients$453,796
R61 · FY2022 · HL · contact PI
1/2 Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases study$2,748,291
UH3 · FY2021 · HL · contact PI
Understanding the Origins of Early COPD$2,263,283
R01 · FY2021 · HL · contact PI
The CAPTURE Study: Validating a unique COPD screening tool in primary care$1,983,602
R01 · FY2021 · HL · contact PI
Multidisciplinary Approach Training in Respiratory Research$528,413
T32 · FY2021 · HL · contact PI
Clinical Biorepository Core$379,824
P01 · FY2021 · HL · contact PI
Understanding the Origins of Early COPD$2,499,040
R01 · FY2020 · HL · contact PI
The CAPTURE Study: Validating a unique COPD screening tool in primary care$2,056,934
R01 · FY2020 · HL · contact PI
Multidisciplinary Approach Training in Respiratory Research$520,378
T32 · FY2020 · HL · contact PI
The CAPTURE Study: Validating a unique COPD screening tool in primary care$2,062,326
R01 · FY2019 · HL · contact PI
1/2 Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases study$976,537
UG3 · FY2019 · HL · contact PI
Multidisciplinary Approach Training in Respiratory Research$337,517
T32 · FY2019 · HL · contact PI
The CAPTURE Study: Validating a unique COPD screening tool in primary care$2,213,604
R01 · FY2018 · HL · contact PI
Study of Co-trimoxazole and Proton Pump Inhibition Using Pragmatic Design in Idiopathic Pulmonary Fibrosis - CleanUP-IPF$360,335
U01 · FY2018 · HL · contact PI
Multidisciplinary Approach Training in Respiratory Research$162,485
T32 · FY2018 · HL · contact PI
The CAPTURE Study: Validating a unique COPD screening tool in primary care$2,419,738
R01 · FY2017 · HL · contact PI
Parametric Response Mapping in COPD$687,186
R01 · FY2017 · HL
Study of Co-trimoxazole and Proton Pump Inhibition Using Pragmatic Design in Idiopathic Pulmonary Fibrosis - CleanUP-IPF$360,316
U01 · FY2017 · HL · contact PI
Parametric Response Mapping in COPD$272,378
R01 · FY2017 · HL
Parametric Response Mapping in COPD$1,001,078
R01 · FY2016 · HL
Study of Co-trimoxazole and Proton Pump Inhibition Using Pragmatic Design in Idiopathic Pulmonary Fibrosis - CleanUP-IPF$360,120
U01 · FY2016 · HL · contact PI
Study of Co-trimoxazole and Proton Pump Inhibition Using Pragmatic Design in Idiopathic Pulmonary Fibrosis - CleanUP-IPF$156,617
U01 · FY2016 · HL · contact PI
Parametric Response Mapping in COPD$903,303
R01 · FY2015 · HL
Study of Co-trimoxazole and Proton Pump Inhibition Using Pragmatic Design in Idiopathic Pulmonary Fibrosis - CleanUP-IPF$394,610
U01 · FY2015 · HL · contact PI
Pulmonary bacterial microbiome-epithelial cell interactions in COPD$382,189
R01 · FY2015 · HL
Parametric Response Mapping in COPD$110,438
R01 · FY2015 · HL
Parametric Response Mapping in COPD$1,015,251
R01 · FY2014 · HL
Design and Testing of tools to Identify individuals at high risk for COPD 73$993,132
R01 · FY2014 · HL · contact PI
Pulmonary bacterial microbiome-epithelial cell interactions in COPD$380,266
R01 · FY2014 · HL
Beneficial effects of quercetin in COPD - a preliminary clinical trial$52,886
R21 · FY2014 · AT
Design and Testing of tools to Identify individuals at high risk for COPD 73$889,324
R01 · FY2013 · HL · contact PI
Pulmonary bacterial microbiome-epithelial cell interactions in COPD$369,372
R01 · FY2013 · HL
Design and Testing of tools to Identify individuals at high risk for COPD^ 73$556,256
R01 · FY2012 · HL · contact PI
Prostanoids, Plasminogen Actication, and Personalized Therapeutics in IPF$446,234
P50 · FY2012 · HL
Pulmonary bacterial microbiome-epithelial cell interactions in COPD$401,882
R01 · FY2012 · HL · contact PI
Beneficial effects of quercetin in COPD - a preliminary clinical trial$194,375
R21 · FY2012 · AT
Prostanoids, Plasminogen Actication, and Personalized Therapeutics in IPF$446,234
P50 · FY2011 · HL
CTRIP: Molecular phenotypes of rapidly progressive idiopathic pulmonary fibrosis$3,695,556
RC2 · FY2010 · HL · contact PI
CTRIP: Molecular phenotypes of rapidly progressive idiopathic pulmonary fibrosis$4,219,951
RC2 · FY2009 · HL · contact PI
Novel Therapeutic Approaches in IPF$293,041
U10 · FY2009 · HL · contact PI
Novel therapies in idiopathic pulmonary fibrosis$84,747
K24 · FY2009 · HL · contact PI
Novel Therapeutic Approaches in IPF$283,432
U10 · FY2008 · HL · contact PI
Novel therapies in idiopathic pulmonary fibrosis$84,906
K24 · FY2008 · HL · contact PI
Strategies to Prevent COPD Exacerbation$435,905
U10 · FY2007 · HL · contact PI
Novel Therapeutic Approaches in IPF$285,492
U10 · FY2007 · HL · contact PI
Novel therapies in idiopathic pulmonary fibrosis$85,061
K24 · FY2007 · HL · contact PI
EFFECT OF CHRON MACROLIDE ADMIN ON FREQUENCY & SEVERITY OF COPD EXACERBATIONS$30,053
M01 · FY2007 · RR · contact PI
Strategies to Prevent COPD Exacerbation$527,701
U10 · FY2006 · HL · contact PI
CORE--CLINICAL$359,880
P50 · FY2006 · HL · contact PI
Novel Therapeutic Approaches in IPF$289,978
U10 · FY2006 · HL · contact PI
Novel therapies in idiopathic pulmonary fibrosis$85,210
K24 · FY2006 · HL · contact PI
Strategies to Prevent COPD Exacerbation$738,400
U10 · FY2005 · HL
CORE--CLINICAL$351,932
P50 · FY2005 · HL
Novel Therapeutic Approaches in IPF$292,565
U10 · FY2005 · HL
Novel therapies in idiopathic pulmonary fibrosis$83,812
K24 · FY2005 · HL
Strategies to Prevent COPD Exacerbation$340,056
U10 · FY2004 · HL
PREDICTING RESPONSE TO THERAPY IN IDIOPATHIC PULMONARY F$203,674
K24 · FY2004 · HL
PREDICTING RESPONSE TO THERAPY IN IDIOPATHIC PULMONARY F$116,833
K24 · FY2003 · HL
PREDICTING RESPONSE TO THERAPY IN IDIOPATHIC PULMONARY F$71,390
K24 · FY2003 · HL
CORE--CLINICAL$208,827
P50 · FY2002 · HL
PREDICTING RESPONSE TO THERAPY IN IDIOPATHIC PULMONARY F$116,812
K24 · FY2002 · HL
CORE--CLINICAL$208,827
P50 · FY2001 · HL
PREDICTING RESPONSE TO THERAPY IN IDIOPATHIC PULMONARY F$116,791
K24 · FY2001 · HL
CORE--CLINICAL$255,534
P50 · FY2000 · HL
PREDICTING RESPONSE TO THERAPY IN IDIOPATHIC PULMONARY F$116,772
K24 · FY2000 · HL